Table 2.
Initial empirical antibiotic therapy and clinical outcomes of P. aeruginosa bloodstream infection compared by group.
| Characteristics | No Septic Shock n = 802 (%) |
Septic Shock n = 411 (%) |
p-Value |
|---|---|---|---|
| Empirical antibiotic therapy | |||
| Monotherapy | 514 (65.1) | 221 (54.7) | <0.001 |
| Combination therapy | 276 (34.9) | 183 (45.3) | <0.001 |
| Both antibiotics with in vitro activity | 213 (27) | 120 (29.7) | 0.324 |
| β-lactam + aminoglycoside | 165 (20.9) | 93 (23) | 0.403 |
| β-lactam + non-aminoglycoside | 46 (5.8) | 26 (6.4) | 0.678 |
| Combination without β-lactam | 1 (0.1) | 5 (1.2) | 0.019 |
| Inadequate empirical antibiotic therapy | 130 (16.2) | 89 (21.7) | 0.020 |
| Carbapenems | 44 (33.8) | 36 (40.4) | |
| Piperacillin–tazobactam | 39 (30) | 23 (25.8) | |
| Fluoroquinolones | 12 (9.2) | 3 (3.3) | |
| Ceftriaxone | 6 (4.6) | 2 (2.2) | |
| Aminoglycosides | 2 (1.5) | 3 (3.3) | |
| Glycopeptides | 2 (1.5) | 2 (2.2) | |
| Antipseudomonal cephalosporins | 1 (0.76) | 2 (2.2) | |
| Cotrimoxazole | 1 (0.76) | 1 (1.1) | |
| Tigecycline | 2 (1.5) | 1 (1.1) | |
| Other | 21 (16.1) | 16 (17.9) | |
| Granulocyte colony-stimulating factor | 424 (53.6) | 198 (48.5) | 0.096 |
| Intensive care unit admission | 84 (10.5) | 304 (74) | <0.001 |
| Invasive mechanical ventilation | 45 (5.6) | 201 (49.1) | <0.001 |
| Persistent bloodstream infection | 61 (7.7) | 73 (18.3) | <0.001 |
| Early case fatality rate (7 days) | 97 (12.1) | 239 (58.2) | <0.001 |
| Overall case fatality rate (30 days) | 185 (23.1) | 304 (74) | <0.001 |